Endpoints News

Karyopharm’s mixed myelofibrosis data; Rezolute to seek FDA approval despite trial failure

Published

2 weeks ago

on

March 24, 2026

By

Temp User

Plus, news about Aardvark Therapeutics, RA Capital, Gilead and EpiFrontier:

📊 Karyopharm’s late-phase myelofibrosis data: The company’s drug selinexor achieved one co-primary endpoint but missed on the other in a …

Related Topics:

Leave a Reply

Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Contributors9 years ago

The final 6 ‘Game of Thrones’ episodes might feel like a full season
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Uncategorized9 years ago

The old and New Edition cast comes together to perform
Uncategorized9 years ago

Phillies’ Aaron Altherr makes mind-boggling barehanded play
Uncategorized9 years ago

Uber and Lyft are finally available in all of New York State

Exit mobile version